FindTrial
Sign In

Comparison of milrinone and heparin via inhalational route for the improvement of oxygenation in acute respiratory failure patients.

Comparative evaluation of milrinone versus heparin nebulization for the improvement of oxygenation in acute respiratory distress syndrome: a randomized controlled trial. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/078416
Enrollment
90
Registered
2024-12-23
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J960- Acute respiratory failure

Interventions

Intervention1: Nebulization with 5 mg Milrinone every 6 hour for 72 hour.: In addition to routine care patients will receive, 5mg of nebulized milrinone via inhalational route every 6 hour for 72 hour

Sponsors

All India Institute of Medical Sciences Patna
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Mild and moderate ARDS based on Berlins criteria

Exclusion criteria

Exclusion criteria: Patient on multiple ionotropes Allergy to the drugs Psychiatric patients Consent not given Pulmonary artery hypertension Heart failure Coagulopathy C

Design outcomes

Primary

MeasureTime frame
To compare the respiratory index after nebulization between heparin and milrinone.Timepoint: After 72 hours of nebulization—

Secondary

MeasureTime frame
To compare the respiratory index (PaO2/FiO2)Timepoint: At Pre-nebulization, 1 hour, 6-hour, 12-hour,24-hour, 48-hour and 72 hours after initiation of nebulization.;To compare Dead space ventilationTimepoint: At Pre-nebulization, 1 hour, 6-hour, 12-hour,24-hour, 48-hour and 72 hours after initiation of nebulization;To assess Improvement in interstitial oedema by measuring B-line score using USG.Timepoint: At base line, 24 hour and 72 hour after initiation of nebulization.;Comparison of 28 days mortality among both groupsTimepoint: 28 days—

Countries

India

Contacts

Public ContactDr Fathima Femi KK

AIIMS Patna

amarjeetdmch@gmail.com9570890646

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026